Skip navigationU.S. Food and Drug Administration Center for Drug Evaluation and Research

CDER - Center for Drug Evaluation and Research Logo

Office of Generic Drugs

Reference Listed Drug Labeling and Efficacy Supplements Approved in September 2002
Click on appropriate hyperlink below to view available source document in PDF format

Approval

Date

Product Name

Source Documents

Active Ingredient(s)/Dosage Form

Document ID No.

ALDARA

letter

label

imiquimod cream

20-723

SLR 012

CYCLOCORT

letter

label

amcinonide ointment

18-498

SLR 008

Sep 3

KENALOG IN ORABASE

letter

label

triamcinolone acetonide dental paste

12-097

SLR 016

REBETOL

    

label

ribavirin capsules

20-903

SLR 023

   

WESTCORT

letter

label

hydrocortisone valerate ointment

18-726

SLR 012

Sep 5

ARIMIDEX

letter

label

anastrozole tablets

20-541

SE1 010

LESCOL

letter

label

fluvastatin Na capsules

20-261

SLR 032

Sep 6

LESCOL XL

letter

label

fluvastatin Na extended-release tablets

21-192

SLR 004

   

PURINETHOL

letter

   

mercaptopurine tablets

09-053

SLR 021

Sep 8

NICOTROL 

letter

   

nicotine inhalation system

20-714

SLR 010

  

NICOTROL NS

letter

   

nicotine nasal spray

20-385

SLR 005

Sep 9

VALTREX

letter

   

valacyclovir HCl tablets

20-550

SE1 016

Sep 11

ALTOCOR

letter

label

lovastatin extended-release tablets

21-316

SE1 001

    

SPORANOX

letter

label

itraconazole oral solution

20-657

SLR 007

Sep 12

HIVID

letter

label

zalcitabine tablets

20-199

SLR 016

Sep 13

ATACAND

letter

label

candesartan cilexetil tablets

20-838

SE4 015

Sep 16

COLYTE

letter

   

PEG and electrolytes) oral solution

18-983

SLR 035

    

FOSAMAX

letter

label

alendronate sodium tablets

20-560

SLR 028

Sep 17

AVAPRO

letter

label

irbesartan tablets

20-757

SE1 021

      

COZAAR

letter

label

losartan potassium tablets

20-386

SE1 028

Sep 18

ZOLOFT

letter

  

sertraline HCl tablets

19-839

SLR 043

     

ZOLOFT

letter

   

sertraline HCl oral concentrate

20-990

SLR 009

Sep 19

CRIXIVAN

letter

label

indinavir sulfate capsules

20-685

SLR 055

GOLYTELY

letter

   

PEG-3350/electrolytes for oral solution

19-011

SLR 015

  

VIAGRA

letter

label

sildenafil citrate tablets

20-895

SLR 015

CANCIDAS

letter

label

caspofungin acetate injection

21-227

SE1 001

MEVACOR

letter

label

lovastatin tablets

19-643

SLR 071

NEXIUM

letter

   

esomeprazole Mg delayed-release capsules

21-153

SLR 005

Sep 20

SUSTIVA

letter

    

efavirenz tablets

20-972

SLR 017

SUSTIVA

letter

    

efavirenz capsules

21-360

SLR 001

ZOLOFT

letter

    

sertraline HCl tablets

19-839

SE8 036

   

ZOLOFT

letter

   

sertraline HCl oral concentrate

20-990

SE8 004

Sep 23

ACIPHEX

letter

    

rabeprazole Na delayed-release tablets

20-973

SLR 014

ADRIAMYCIN PFS

letter

label

doxorubicin HCl injection

50-629

SLR 010

Sep 25

ADRIAMYCIN RDF

letter

label

doxorubicin HCl for injection

50-467

SLR 067

VIDEX

letter

label

didanosine tablets

20-155

SLR 030

  

VIDEX

letter

label

didanosine for oral solution

20-154

SLR 041

Sep 27

PROTOPAM

letter

label

pralidoxime Cl for injection,

14-134

SLR 024

 

GLUCOVANCE

letter

label

glyburide/metformin HCl tablets

21-178

SE1 004

Sep 30

HYPAQUE

letter

   

diatrizoate meglumine

16-403

SLR 071

  

PROHANCE

letter

    

gadoteridol injection

20-131

SLR 016

    

REMERON

letter

    

mirtazapine tablets

20-415

SLR 015

totop.gif (1525 bytes) Back to Top

Back Labeling Review Branch Page

FDA/Center for Drug Evaluation and Research
Last Updated: January 18, 2006
Originator: OTCOM/DLIS
HTML by JFG